JAZZ
Price
$118.23
Change
+$0.22 (+0.19%)
Updated
Jul 25 closing price
Capitalization
7.15B
10 days until earnings call
TECH
Price
$58.78
Change
+$0.31 (+0.53%)
Updated
Jul 25 closing price
Capitalization
9.21B
11 days until earnings call
Interact to see
Advertisement

JAZZ vs TECH

Header iconJAZZ vs TECH Comparison
Open Charts JAZZ vs TECHBanner chart's image
Jazz Pharmaceuticals
Price$118.23
Change+$0.22 (+0.19%)
Volume$549.7K
Capitalization7.15B
Bio-Techne
Price$58.78
Change+$0.31 (+0.53%)
Volume$2.7M
Capitalization9.21B
JAZZ vs TECH Comparison Chart in %
Loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAZZ vs. TECH commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Buy and TECH is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (JAZZ: $118.23 vs. TECH: $58.78)
Brand notoriety: JAZZ and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 80% vs. TECH: 120%
Market capitalization -- JAZZ: $7.15B vs. TECH: $9.21B
JAZZ [@Biotechnology] is valued at $7.15B. TECH’s [@Biotechnology] market capitalization is $9.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 1 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, TECH is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 6 TA indicator(s) are bullish while TECH’s TA Score has 5 bullish TA indicator(s).

  • JAZZ’s TA Score: 6 bullish, 3 bearish.
  • TECH’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, JAZZ is a better buy in the short-term than TECH.

Price Growth

JAZZ (@Biotechnology) experienced а +4.75% price change this week, while TECH (@Biotechnology) price change was +12.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

JAZZ is expected to report earnings on Nov 05, 2025.

TECH is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($9.22B) has a higher market cap than JAZZ($7.15B). TECH has higher P/E ratio than JAZZ: TECH (70.82) vs JAZZ (16.06). JAZZ YTD gains are higher at: -3.995 vs. TECH (-18.164). JAZZ has higher annual earnings (EBITDA): 1.25B vs. TECH (283M). JAZZ has more cash in the bank: 2.57B vs. TECH (141M). TECH has less debt than JAZZ: TECH (423M) vs JAZZ (5.42B). JAZZ has higher revenues than TECH: JAZZ (4.07B) vs TECH (1.21B).
JAZZTECHJAZZ / TECH
Capitalization7.15B9.22B78%
EBITDA1.25B283M441%
Gain YTD-3.995-18.16422%
P/E Ratio16.0670.8223%
Revenue4.07B1.21B336%
Total Cash2.57B141M1,824%
Total Debt5.42B423M1,281%
FUNDAMENTALS RATINGS
JAZZ vs TECH: Fundamental Ratings
JAZZ
TECH
OUTLOOK RATING
1..100
1673
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
6180
PRICE GROWTH RATING
1..100
5153
P/E GROWTH RATING
1..100
8639
SEASONALITY SCORE
1..100
8n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is significantly better than the same rating for JAZZ (70) in the Pharmaceuticals Other industry. This means that TECH’s stock grew significantly faster than JAZZ’s over the last 12 months.

JAZZ's Profit vs Risk Rating (89) in the Pharmaceuticals Other industry is in the same range as TECH (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

JAZZ's SMR Rating (61) in the Pharmaceuticals Other industry is in the same range as TECH (80) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

JAZZ's Price Growth Rating (51) in the Pharmaceuticals Other industry is in the same range as TECH (53) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

TECH's P/E Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for JAZZ (86) in the Pharmaceuticals Other industry. This means that TECH’s stock grew somewhat faster than JAZZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAZZTECH
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
64%
Momentum
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
67%
Advances
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
71%
Declines
ODDS (%)
Bearish Trend 8 days ago
56%
Bearish Trend 5 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JAOSX53.16N/A
N/A
Janus Henderson Overseas T
GSSQX66.05N/A
N/A
Goldman Sachs US Equity Insights A
AABPX12.07N/A
N/A
American Beacon Balanced Inv
RSNYX42.51N/A
N/A
Victory Global Energy Transition Y
RIRBX77.74-0.04
-0.05%
American Funds Capital Income Bldr R2